Visus Therapeutics has started a clinical development program for an eye drop designed to restore loss of near vision due to presbyopia, according to a press release.
The program’s lead candidate, Brimochol, combines FDA-approved carbachol and brimonidine tartrate and has undergone five clinical studies investigating efficacy and safety. The most recent study, carried out in 57 patients, showed a statistically significant improvement of near visual acuity of five Jaeger lines or more for at least 12 hours. No headaches or browaches were reported.
Phase 2 trials are expected to begin in
Uncategorized